MYH9 and APOL1 Gene Polymorphisms and the Risk of CKD in Patients with Lupus Nephritis from an Admixture Population

Vinicius Sardão Colares1, Silvia Maria de Oliveira Titan1, Alexandre da Costa Pereira2, Patrícia Malafrente1, Mari M. Cardena3, Sidney Santos4, Paulo C. Santos2, Cintia Fridman3, Rui Toledo Barros1, Viktória Woronik1*

1 Nephrology Division, Hospital das Clínicas, Sao Paulo University Medical School, Sao Paulo, Sao Paulo, Brazil, 2 Molecular Cardiology Laboratory, Heart Institute (InCor), Sao Paulo University Medical School, Sao Paulo, Sao Paulo, Brazil, 3 Department of Legal Medicine, Ethics and Occupational Health, Medical School, University of São Paulo, Sao Paulo, Sao Paulo, Brazil, 4 Laboratory of Human Genetics and Medicine, Federal University of Pará, Belém, Pará, Brazil

Abstract

MYH9 polymorphisms have been described to be associated with the risk of CKD in non-diabetic nephropathy, HIV nephropathy and FSGS [1–4]. The two genes co-segregate with MYH9 gene polymorphisms and the risk of CKD in Patients with Lupus Nephritis from an Admixture Population. The objective of our study was to evaluate the relationship between MYH9 and APOL1 gene polymorphisms and the risk of CKD in LN Brazilian patients, a highly admixed population.

Introduction

Polymorphisms in the non-muscle heavy chain 9 (MYH9) gene have been associated to the risk of chronic kidney disease (CKD) in populations with non-diabetic kidney disease, HIVAN, and idiopathic FSGS [1–4]. The risk variants are particularly common in African descendants and MYH9 polymorphisms have been proposed to contribute to approximately 70% of non-diabetic forms of ESRD in African Americans (AA) and to 40 to 45% of all ESRD in this ethnic group [5]. These first results led to the hypothesis that MYH9 could be a major determinant of the excess risk of CKD associated with African ancestry.

However, in 2010, it was proposed that APOL1 gene polymorphisms were more intensely associated to the CKD risk, previously attributed to MYH9 [6,7]. The two genes co-segregate in many populations making it difficult to differentiate between the two association signals. In addition, MYH9 gene polymorphism was not shown to be associated with CKD in non-African populations, such as in American Indians [8].

African ancestry has also been proposed to be associated with a higher incidence of CKD in lupus nephritis (LN) [9]. However, MYH9 polymorphisms have not been shown to be associated with ESRD in African Americans patients with LN [10]. Recently, MYH9 polymorphisms (but not APOL1) have been implicated in the risk of LN in European Americans and in Gullah populations. No association was found between LN and MYH9 in AAs [11].

The objective of our study was to evaluate the relationship between MYH9 and APOL1 gene polymorphisms and the risk of CKD in LN Brazilian patients, a highly admixed population.

Study Population and Methods

Patients and protocol

Initially, all adult patients with a renal-biopsy confirmed diagnosis of LN undergoing regular follow-up in the Nephrology Division between July 2005 and July 2007 were enrolled. Patients with diabetes, hepatitis B, hepatitis C, HIV or those who had less than 3 months of follow-up were excluded, leaving for the analysis 196 female patients.
All patients fulfilled the American College of Rheumatology 1982 revised criteria [12]. LN was determined according to the WHO classification [13]. Treatment was determined by the attending physician. The most common therapeutic regimen for patients with class IV disease was intravenous and/or oral corticosteroids associated with intravenous cyclophosphamide (more than 90% of class IV nephritis), administered according to the US National Institutes of Health protocol [14]. For those with a good response at 6 months of treatment, conversion to azathioprine or mycophenolate mofetil was common. Patients with class V LN were mostly treated with oral corticosteroids and/or cytotoxic drugs [15] (approximately 50% of patients received cyclophosphamide and corticosteroids). Laboratory testing was periodically performed to determine serum creatinine, complement, antinuclear antibody (ANA), double stranded DNA (dsDNA), blood cell counts, proteinuria, and urinalysis. ANA was determined by immunofluorescence in Hep-2 cells, anti-dsDNA by immunofluorescence using *Crithidia luciae* as substrate, and complement by radial immunodiffusion.

Race was assessed by three different ways: a physician-assessed classification of skin color, based solely on a visual and subjective estimation of the ancestry of the patient, as done before [16]; by mitochondrial haplogroup and by autosomal genetic ancestry [17].

Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) and renal disease activity by the renal SLEDAI score [18]. Renal flare was defined as (i) the recurrence or the development of nephrotic syndrome (serum albumin ≤3.5 g/dl and 24 h proteinuria ≥3 g; (ii) renal impairment (≥33% increase of serum creatinine within a 1-month period directly attributed to lupus and confirmed 1 week later; flare referred to as ‘nephritic flare’) or (iii) a threefold increase of 24 h proteinuria within a 3-month period accompanied by microscopic haematuria (defined as a number of red blood cells (RBC) per high power field superior to upper normal limit for the local laboratory) and ≥33% reduction of serum C3 level within a 3-month period, only to those patients with low grade baseline 24 h proteinuria (≥0.5 g and <1 g). Renal remission was defined as a serum creatinine ≤1.4 mg/dl and a 24 h proteinuria <0.3 g and a urinary RBC count <10/ high power field, at any time of follow-up. Partial remission was defined by a 24 h proteinuria between 0.3 and 2.9 g, or a proteinuria drop >50% from the baseline, at any time of follow-up. The renal function should be stable [19].

Primary outcome (PO) was defined as duplication of serum creatinine or need of renal replacement therapy. PO status was defined by data collected at baseline (around one week before renal biopsy) and at the last follow-up examination until to December 2010.

The study was approved by the Research Ethics Committee of our hospital (Comissão de Ética para Análise de Projetos de Pesquisa – CAPPesq – Hospital das Clínicas – Faculdade de Medicina da Universidade de São Paulo) and all patients provided written informed consent.

**SNP Selection and Genotyping**

Genomic DNA from subjects was extracted from peripheral blood following standard salting-out procedure [20]. Polymorphisms for the MYH9 rs4821481, rs2032487, rs4821481, rs3752462 (E1 haplotype), for APOL1 rs73885319, rs16996616, rs60910145, rs71785313, and APOL3 rs11089781 were determined by high resolution melting technique (HRM) (Rotor Gene 6000, Qiagen, Courtaboeuf, France). The QIAgility (Qiagen, Courtaboeuf, France) is an automated instrument that was used to optimize the sample preparation step in the PCR-HRM. In each genotyping assay, 96 samples were genotyped in a specific disc, and samples of three pattern genotypes inserted. Polymorphic regions were amplified by adding 1 μl of genomic DNA to solution of 10 μMTris-HCl (pH = 9), 50 mM KCl, 2.5 mM MgCl2, 100 mM of each dNTP, 0.5 U of Easy Taq DNA Polymerase (Invitrogen), and 5 pmol of each primer. Amplification of the fragments was performed using the primer sense ras4821481F: CCTACAGGCTGTCCGCAAGCTCAGG; rs4821481R: AGAGGGGGAAGGAGCAGACACCTTCC; rs2032487F: AGAGGCTGCCACACGGGCTCACCCTG; rs2032487R: GCCACACGGGACCTTTCCTCGGCC; rs4821480F: ATTTTCTAGATCAAGGATAATTIT; rs4821480R: AAAGGTCAAGAGTCCCGCTCCCTGAAACA; rs3752462F: CAGGTGTAGGCTCAAGCAGAGCCAAGGC; rs3752462R: ACTCAGCTGCTTCTCAATGAGGTG; rs73885319F: CCTGGAAATGAGCAGAGAG; rs73885319R: CATCCAGACAAAGAAGGAAAGCG; rs60910145F: CTCAGGAAGCTGGAGAGAAG; rs60910145R: GCCCTGTGCTGACAGTTCTCT; rs11089781F: TGGAGAACGTGCTGCTGTATTA; rs11089781R: GCAAGATCAGCAGTCTGCTG.

A 30-cycle PCR was carried out using the following conditions: denaturation of the template DNA for first cycle at 94°C for 120 s, denaturation at 94°C for 20 s, specific annealing temperature for 20 s, and extension at 72°C for 22 s. PCR was performed using a 10 μl reaction mixture (10 mM Tris–HCl, 50 mM KCl, pH 9.0, 2.0 mM MgCl2; 200 μM of each dNTP; 0.5 U Taq DNA Polymerase; 200 nM of each primer; 10 ng of genomic DNA template). 200 nM of each primer; 10 ng of genomic DNA template) with addition of fluorescent DNA intercalating SYTO9 (1.5 μM; Invitrogen, Carlsbad, USA).

In the HRM phase, the Rotor Gene 6000 measured the fluorescence in each 0.1°C temperature increase in the range of 70–90°C. Melting curve was generated by the decrease in fluorescence with the increase in the temperature; and in analysis, nucleotide changes results in three different curve patterns. Samples of the three observed curves were sequenced (ABI Terminator Sequencing Kit and ABI 3500XL Sequencer—Applied Biosystems, Foster City, CA, USA) to confirm the genotypes identified by HRM analysis. In addition, 10% of the samples were reanalyzed as quality control and gave identical results.

**Statistical analysis**

Mann-Whitney and chi-square tests were used for comparison among continuous and categorical variables, respectively. Hardy-Weinberg equilibrum for the genotypes was tested by chi-square goodness-of-fit test. Linkage Disequilibrium (LD) was estimated using r2 and χ2 statistics using Haploview 3.32. Hapstat (http://www.bios.unc.edu/~dlin/hapstat/) was used for comparisons of SNPs and frequency of the PO, using dominant, additive, and recessive models. Cox proportional hazard models (SPSS v13.0) were built for the risk of the PO according to MYH9 and APOL1 genotypes using dominant, recessive models. Cox proportional hazard models (SPSS v13.0) were built for the risk of the PO according to MYH9 and APOL1 genotypes. Cox proportional hazard models (SPSS v13.0) were built for the risk of the PO according to MYH9 and APOL1 genotypes and also according to the MYH9 E1 haplotype (determined using Haplovie). Kaplan-Meier curve of the PO according to MYH9 E1 haplotype was created and log-rank test calculated. All tests were two-sided and considered significant if p value <0.05.

**Results**

In Table 1, baseline clinical, laboratorial and histological data of the 196 female patients with LN are shown. Patients were young, and presented high creatinine, low estimated creatinine clearance, high proteinuria and 66% of proliferative forms of LN. Of the 196 patients enrolled, 62 presented the PO (end-stage renal disease or
creatinine duplication), with a mean follow-up time of 6.2 years. As expected, patients who presented the PO had a higher percentage of hypertension, lower C3 level, high serum creatinine and lower estimated creatinine clearance and higher percentage of proliferative forms than those without the PO. In addition, chronicity index, number of fibroblastic crescents and tubule-interstitial fibrosis at baseline were significantly higher in those who presented the PO. Poor response to treatment and occurrence of renal flares were also more common in the PO group. Interestingly, only one third of the population self-reported race as black or mulatto (nearly 65% self-reported race as white), with no difference according to the PO. Analyzing data of mitochondrial haplogroup, there was approximately 50% of African, 30% of Ameridian and less than 15% European ancestry in our sample. This distribution was not different according to PO (p = 0.42). Autossomal ancestry was not different among groups either, with approximately 30% of African genes present in our sample.

Table 1. Baseline clinical, laboratorial and histological data of 196 LN patients and according to renal outcome.

|                              | All patients (n = 196) | non ESRD-CD (n = 134) | ESRD-CD (n = 62) | p*     |
|------------------------------|------------------------|-----------------------|------------------|--------|
| Age (years; mean/stand)      | 28.6 9.8               | 28.5 9.5              | 28.9 10.5        | 0.88   |
| Physician-assessed skin color (black-mulatto; n%) | 64 32.6               | 45.0 33.6             | 19 30.6          | 0.68   |
| Hypertension (yes; n%)       | 151 77.0               | 95 70.9               | 56 90.3          | 0.003  |
| Creatinine (mg/dL; mean/stand) | 1.6 0.95–3.1          | 2.0 1.6               | 3.8 3.1          | <0.0001|
| Est. creatinine clearance (MDRD, ml/min/1.73 m²; median/IQR) | 50.8 39.7               | 48.3 26.1–85.0        | 23.2 9.0–58.7    | <0.0001|
| Albumin (mg/dL; mean/stand)  | 2.6 0.8                | 2.6 0.9               | 2.6 0.8          | 0.95   |
| 24 h proteinuria (g/d; median/IQR) | 3.9 2.2–6.8            | 3.9 2.3–6.3           | 4.4 1.7–7.0      | 0.65   |
| ANA (positive >1/80; n%)     | 161 82.1               | 110 82.1              | 51 82.3          | 0.98   |
| C3 (mg/dL; median/IQR)       | 58 41.5–81.5           | 63 42.3–86.6          | 51 39.5–67.5     | 0.03   |
| C4 (mg/dL; median/IQR)       | 11 6.2–20              | 12 6.6–20             | 11 6–18          | 0.77   |
| SLEDAI (mean/stand)          | 21.0 6.4               | 20.4 5.9              | 22.2 7.2         | 0.25   |
| RENAL SLEDAI (mean/stand)    | 9.1 3.4                | 8.9 3.6               | 9.7 2.8          | 0.08   |
| Lupus nephritis histologic classification (n%) | | | | |
| III+IV                       | 130 66.3               | 84 62.7               | 46 74.2          | 0.01   |
| V                            | 61 31.1                | 49 36.6               | 12 19.4          |        |
| VI                           | 5 2.6                 | 1 0.7                 | 4 6.5            |        |
| Activity (median/IQR)        | 4 3–5                 | 4 3–6                 | 4 3–5            | 0.93   |
| Chronicity (median/IQR)      | 3 0–5                 | 2 0–4                 | 5 2–7            | <0.0001|
| Number of epithelial crescents (median/IQR) | 0 0–1                  | 0 0–1                 | 0 0–2            | 0.35   |
| Number of fibroblastic crescents (median/IQR) | 0 0–1                 | 0 0–1                 | 0 0–2            | 0.01   |
| Tubulo-interstitial fibrosis (>50% fibrosis; n%) | 18 9.5                 | 6 4.5                 | 12 21.8          | 0.001  |
| Vessels (presence of abnormalities; n%) | 69 35.2                | 41 30.6               | 28 45.2          | 0.05   |
| Renal flare (nephritic or nephrotic; n%) | 93 47.4                | 63 53.8               | 30 81.1          | 0.003  |
| Response to treatment** (n%) | | | | |
| complete remission           | 136 72.7               | 118 88.1              | 18 34.0          | <0.0001|
| partial remission            | 25 13.4                | 13 9.7                | 12 22.6          |        |
| no response                  | 26 13.9               | 3 2.2                 | 23 43.4          |        |
| Race by mitochondrial haplogroup (n%) | | | | |
| African                      | 91 46.4                | 60 46.5               | 31 56.4          | 0.42   |
| Ameridian                    | 62 31.6                | 45 34.9               | 17 30.9          |        |
| European                     | 31 15.8                | 24 18.6               | 7 12.7           |        |
| Race by autossomal ancestry (mean/stand) | | | | |
| African                      | 0.31 0.17              | 0.29 0.17             | 0.33 0.18        | 0.23   |
| Ameridian                    | 0.16 0.09              | 0.16 0.09             | 0.17 0.08        | 0.11   |
| European                     | 0.53 0.18              | 0.55 0.18             | 0.49 0.17        | 0.11   |

*p = Mann-Whitney or chi-square.
** 9 patients were excluded because treatment was not performed or interrupted.
IQR, interquartile range.
doi:10.1371/journal.pone.0087716.t001
In our sample, linkage disequilibrium structure of the \textit{MYH9} and \textit{APOL1} (Figure 1) showed that the four \textit{MYH9} polymorphisms segregate as an haplotype. Importantly, \textit{APOL1} markers were not in linkage disequilibrium with \textit{MYH9} LD block.

Firstly, we analysed the association between each polymorphism and the risk of PO (Table 2). In these analyses, only rs3752462 polymorphism was associated with the PO (using a recessive model), with an adjusted HR of 3.72 (1.47–9.38, \( p = 0.005 \)) for the risk of CKD (Table 3).

\textit{MYH9} E1 haplotype (homo or heterozygous) was present in 29.7\% of cases and in 18.5\% of controls. By Cox regression analyses, presence of at least one \textit{MYH9} E1 haplotype was significantly associated with the risk of the PO [HR 1.0, 95\% CI 1.1–2.9, \( p = 0.02 \); Figure 2]. After adjustment for estimated creatinine clearance and African autosomal ancestry, \textit{MYH9} E1 haplotype remained associated to the risk of CKD [HR 2.0, 95\% CI 1.2–3.4, \( p = 0.01 \)] . Kaplan Meier curve is also shown in Figure 2, with a log rank \( p \) value of 0.02. No difference in the model was shown by repeating the analyses with adjustment for mitochondrial haplogroup and also by including both African and Ameridian or European ancestry as covariates.

Lastly, we analysed clinical and laboratorial baseline data according to \textit{MYH9} E1 haplotype, in order to evaluate if genotype was related to lupus activity (Table 4). The only difference found was that people with the GCCT haplotype presented a higher percentage of class VI LN, suggesting that the haplotype is not related to lupus activity, but only to the risk of chronicity and CKD. Interestingly, the degree of proteinuria was not correlated with the GCCT group.

\section*{Discussion}

The first association between \textit{MYH9} and kidney disease derived from the observation that patients with the giant platelet syndromes, a group of diseases related to \textit{MYH9} mutations and with a spectrum of abnormalities including low platelet count, giant platelets, hearing loss, and cataract, may present FSGS. In 2008, a genome-wide association study proposed that \textit{MYH9} was very strongly associated to HIVAN and idiopathic FSGS [4]. This finding was later confirmed in non-diabetic nephropathy in African Americans [1] and even in the setting of diabetic nephropathy [21]. This led to the hypothesis that \textit{MYH9} could be the gene majorly determinant of the excess risk of CKD in African descendants. However, in 2010, two studies [6,7] re-evaluated this initial finding and suggested that \textit{APOL1}, a neighbor gene presenting very strong co-segregation with \textit{MYH9} in African descendants, presented an even stronger association to CKD than \textit{MYH9}, being the marker possibly responsible for the effect previously attributed to \textit{MYH9} [22]. It was proposed that the \textit{APOL1} variants (called G1 haplotype, related to rs73885319 and rs60910145 polymorphisms, the most frequent type and G2, related to rs71785313 mutation), mutually exclusive (too close for recombination), suffered natural selection in Africa due to an adaptative response related to trypanosomiasis, particularly to some resistant forms prevalent in the sub-Saharan Africa (\textit{Trypanosoma brucei rhodesiense} and \textit{gambiense}). \textit{APOL1} is known to be a trypanolytic factor. Resistant forms of trypanosomiasis exhibit a protein (SRA) that interacts with \textit{APOL1}, reducing its trypanolytic activity. Serum of patients carrying the G1 and G2 variants presented a higher lytic ability than serum of those patients not carrying these variants [7]. Another interesting fact is that the \textit{APOL1} variants were not found in HIV Ethiopian
individuals, described previously for the absence of HIVAN [23]. APOL1 has now been demonstrated to be related to HIVAN and FSGS [24], to collapsing nephropathy in lupus patients [25] and to the younger age of initiation of dialysis [26].

In LN, data is scarce and controversial. In the African American population, despite the high frequency of *MYH9* polymorphisms in African and non-African SLE patients [11], no association was found for African American, Hispanics, Asian and Amerindians, even in a sub-analysis including those patients with LN and ESRD. In addition, in this study, the *APOL1* polymorphisms were not associated with LN.

Our results suggest that *MYH9* polymorphisms, and not *APOL1*, are associated with an increased risk of CKD in patients with LN. Interestingly, in this Brazilian sample, the two genes were not in LD. The frequency of the risk alleles of both *MYH9* (29.7% vs. 18.5% in case and controls, respectively) and *APOL1* (approximately 10%) was not as high as those seen in the African American population. Although we could detect a positive association of *MYH9* with ESRD, it is possible that the absence of association between the PO and *APOL1* genes in our study could be due to a relatively small sample size and lack of power, leading to a type II error. However, if the association were solely due to alleles located in the *APOL1* gene and not to alleles located in the *MYH9* gene, we should have found no association in MYH9 region, that, as we have shown, is independent of the *APOL1* region in our sample. Our interpretation of the results is that there is indeed an association signal residing within the MYH9 region. This, by no means imply a causal role of the protein encoded by MYH9 over the studied phenotype. There are several possibilities, including the existence of genetic variants in this genomic region that affect distant genes, even APOL1. In addition, we were able to adjust our analysis by three different, but correlated, measures of ethnicity: physician-assessed skin color, mitochondrial ancestry and autosomal genetic ancestry.

Another limitation of our study is that it was not an inception cohort and this may lead to prognosis bias, since severe cases are more likely to be included, particularly in a tertiary hospital such as ours. However, this bias is likely to be equally distributed among genotypes. Moreover, race, an important determinant of social-educational status and access to medical care, was not statistically different among genotypes.

Lastly, since several SNPs were tested, our results can be criticized considering we performed multiple comparisons, a strategy which may increase the odds of a positive association by random. A correction for this effect would be the best approach, but these corrections are too conservative for the sample size we had in this sample.

In our study, the E1 haplotype was not related to any SLE clinical or laboratorial marker of activity. This fact suggests that the MYH9-APOL1 gene region is probably acting in the risk of CKD not through immunological mechanisms and activation of nephritis itself, but probably through the disregulation of podocyte function (the main cell type so far considered to be related to MYH9-APOL1 genes), with enhancement of proteinuria and glomerulosclerosis.
Several questions arise from all these initial studies regarding the MYH9-APOL1 gene region. 1. The polymorphisms described both for APOL1 genes and MYH9 occur in non-coding areas, and it is still not well understood how these mutations are related to phenotypic changes. One strong possibility is that the mutations modulate protein transcription. This process could either be on the protein itself (a genetic variant in the MYH9 regulating the expression of the MYH9 protein), or on a more distant protein (such as APOL1). This hypothesis, however, needs further confirmation with animal and clinical studies evaluating gene expression. 2. The data gathered so far points to APOL1 as the gene truly involved in the risk of CKD [22]. However, it is necessary to understand how APOL1 could be related to CKD pathogenesis. Scarce data on biological mechanisms are available and evidence still favors MYH9. MYH9 codifies the myosin-IIa, an enzyme present in the podocyte foot process and known to be related to filament movement. In animal studies, mutations in MYH9 are related to phenotypic kidney abnormalities including albuminuria and FSGS [27,28], as well as defects in morphogenesis [29]. HIV-1 downregulates the expression of MYH9 in transgenic mice, a finding confirmed in humans [30]. In addition, MYH9 mutation is related to FSGS in the giant platelet syndromes, a clinical fact that suggests that this protein actually has a role in the podocyte biology.

On the other hand, insights on APOL1 are available from recent data. APOL1 is more strongly expressed in the placenta, lung and liver [31], as well as in heart, pancreas and endothelial cells. Recently, it was shown that APOL1 is also expressed in the glomeruli, with a signal localizing at the cytoplasm of podocytes [32]. It is known to regulate cell death pathways [33], a property possibly related to its trypanolitic activity. A recent study in autopsies showed that APOL1 risk allele carriers presented glomerular and kidney hypertrophy and accelerated nephron loss when compared to controls [34]. In HIVAN, APOL1 G1 and G2 polymorphism has been related to proteinuria [35].

It is clear that MYH9-APOL1-related kidney disease is a very exciting new area in Nephrology. First, it could provide the first genetic tool allowing the identification of patients at increased risk for ESRD in a complex polygenic disease such as CKD, at least in populations in whom the mutations are known to be prevalent. Secondly, comprehension of the biological mechanisms determining proteinuria and CKD in patients presenting these mutations can create opportunity for new therapeutic targets and measures.

### Table 1

|                        | HR   | 95% CI  | p*   |
|------------------------|------|---------|------|
| GCCT vs. No-GCCT       | 1.8  | 1.1     | 2.9  | 0.02 |

* Cox proportional hazard models

**Figure 2. Cox proportional hazard models and Kaplan-Meier curve of the risk of the PO according to MYH9 E1 haplotype.**

doi:10.1371/journal.pone.0087716.g002
Table 4. Baseline clinical, laboratorial and histological data according to MYH9 E1 haplotype groups.

|                                | non GCCT (n = 123) | GCCT (n = 73) | p*   |
|--------------------------------|--------------------|---------------|------|
| Age (years; mean/std)          | 27.8 ± 9.3         | 30 ± 10.5     | 0.15 |
| Physician-assessed skin color  | 43 ± 35.0          | 21 ± 28.8     | 0.37 |
| Hypertension (yes; n/%)         | 93 ± 75.6          | 58 ± 79.5     | 0.54 |
| Creatinine (mg/dL; mean/std)    | 2.5 ± 2.3          | 2.6 ± 2.4     | 0.79 |
| Est. creatinine clearance       | 39.5 ± 193–836     | 41.3 ± 17.9   | 0.70 |
| Albumin (mg/dL; mean/std)       | 2.6 ± 0.9          | 2.6 ± 0.8     | 0.68 |
| 24 h proteinuria (g/d; median/IQR) | 3.9 ± 2.3–6.9     | 3.9 ± 1.9–6.4 | 0.75 |
| ANA (positive >1/80; n/%)       | 104 ± 84.6         | 57 ± 78.1     | 0.25 |
| C3 (mg/dL; median/IQR)          | 62.0 ± 42–86       | 52.8 ± 40–78  | 0.14 |
| C4 (mg/dL; median/IQR)          | 11.0 ± 6–20        | 12.0 ± 7–18   | 0.76 |
| SLEDAI (mean/std)               | 20.7 ± 6.6         | 21.4 ± 6.1    | 0.60 |
| RENAL SLEDAI (mean/std)         | 9.1 ± 3.5          | 9.2 ± 3.2     | 0.74 |
| Lupus nephritis histologic classification (n/%) | 0.01              |               |      |
| III+IV                          | 82 ± 66.7          | 48 ± 65.8     |      |
| V                               | 41 ± 33.3          | 20 ± 27.4     |      |
| VI                              | 0 ± 0.0            | 5 ± 6.8       |      |
| Activity (median/IQR)           | 4 ± 3–5            | 4 ± 3–6       | 0.66 |
| Chronicity (median/IQR)         | 2 ± 1–5            | 3 ± 0–6       | 0.29 |
| Number of epithelial crescents  | 0 ± 0–1            | 0 ± 0–2       | 0.83 |
| Number of fibroblastic crescents| 0 ± 0–1            | 0 ± 0–2       | 0.47 |
| Tubulo-interstitial fibrosis (>50% fibrosis; n/%) | 8 ± 6.8           | 10 ± 13.9     | 0.11 |
| Vessels (presence of abnormalities; n/%) | 48.0 ± 39.0       | 21.0 ± 28.8   | 0.15 |
| Renal flare (nephritic or nephrotic; n/%) | 58 ± 58.6          | 35 ± 63.6     | 0.54 |
| Response to treatment** (n/%)   | 0.22               |               |      |
| complete remission              | 89 ± 74.2          | 47 ± 70.1     |      |
| partial remission               | 18 ± 15.0          | 7 ± 10.4      |      |
| no response                     | 13 ± 10.8          | 13 ± 19.4     |      |
| Race by mitochondrial haplogroup (n/%) | 0.94              |               |      |
| African                         | 56 ± 50.0          | 35 ± 48.6     |      |
| Ameridian                       | 38 ± 33.9          | 24 ± 33.3     |      |
| European                        | 18 ± 16.1          | 13 ± 18.1     |      |
| Race by autossomal ancestry (mean/std) | 0.08             |               |      |
| African                         | 0.32 ± 0.17        | 0.28 ± 0.17   |      |
| Ameridian                       | 0.16 ± 0.09        | 0.17 ± 0.09   |      |
| European                        | 0.52 ± 0.18        | 0.55 ± 0.17   |      |

* p = Mann-Whitney or chi-square.
** 9 patients were excluded because treatment was not performed or interrupted.
IQR, interquartile range.
doi:10.1371/journal.pone.0087716.t004

In conclusion, our study suggests that MYH9 gene polymorphisms and the E1 haplotype are related to the risk of CKD in LN in an admixture population. APOL1 was not related to this risk in our sample, but this result can be related to our small sample size. Comprehension of the biological mechanisms underlying this association is a current challenge for future research.

References

1. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, et al. (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40:1185–92.
2. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, et al. (2009) Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 75:736–45.
3. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, et al. (2010) African ancestry allelic variation at the MYH9 gene contributes to increased

Author Contributions
Conceived and designed the experiments: VSC SMT ACP RTB VW. Performed the experiments: VSC PM MMC SS PCS CF. Analyzed the data: VSC SMT ACP VW. Wrote the paper: VSC SMT ACP VW. Initial data collection: PM.
susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum Mol Genet 19:1816–27.

4. Kopps JB, Smith MV, Nelson GW, Johnson RC, Freedman BI, et al. (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40:121–4.

5. Bostrom MA, Freedman BI (2010) The Spectrum of MYH9-Associated Nephropathy. Clin J Am Soc Nephrol 5:1107–13.

6. Tzur S, Rosset S, Shemer R, Yudkowsky G, Selig S, et al. (2010) Misense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128:345–50.

7. Genovese G, Tonna SJ, Knob AU, Moulds JM, Lisse J, et al. (1999) Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LLUMINA cohort. Lupus in Minority populations: NATURE vs. NURTURE. Lupus 8:197–209.

8. Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, et al. (2012) Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 13:252–8.

9. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, et al. (1999) MYH9 is not associated with lupus nephritis in African Americans. Am J Nephrol 20:66–72.

10. Freedman BI, Edberg JC, Conneau ME, Moulds MJ, Bowden DW, et al. (2010) The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. Arthritis Rheum 52:66–72.

11. Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, et al. (2012) Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 13:232–8.

12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–7.

13. Churg J, Bernstein J, Glassock RJ (1995) Renal Disease: Classification and Atlas of Glomerular Diseases. 2o ed. Igaku-Shoin Medical Pub.

14. Buhaescu I, Covic A, Deray G (2007) Treatment of proliferative lupus nephritis—a critical approach. Semin Arthritis Rheum 36:224–37.

15. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, et al. (1986) Myosin IIA is required for the development of the zebrafish glomerulus. Kidney Int 31:2162–70.

16. Liu CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, et al. (2012) Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 13:252–8.

17. Tzur S, Rosset S, Shemer R, Yudkowsky G, Selig S, et al. (2010) Misense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128:345–50.

18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–40.